Brigatinib Nitroso Impurity 2
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Brigatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the bodys. Brigatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.Brigatinib Nitroso Impurity 2is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Brigatinib Nitroso Impurity 2 CAS NO:NA chemically represented as N-(5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)-N-(2-(dimethylphosphoryl) phenyl)nitrous amide . Synchemia is the leading manufacturing and exporter of Brigatinib Nitroso Impurity 2 . We supply Brigatinib Nitroso Impurity 2 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0141223 |
| CAS No | NA |
| Mol.F. | C25H29F3N4O4 |
| Mol.Wt. | 506.5 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141224 |
| CAS No | NA |
| Mol.F. | C32H33F3N4O5 |
| Mol.Wt. | 610.6 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141225 |
| CAS No | NA |
| Mol.F. | C13H22N4OS |
| Mol.Wt. | 282.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141226 |
| CAS No | NA |
| Mol.F. | C20H31N7OS2 |
| Mol.Wt. | 449.6 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141227 |
| CAS No | NA |
| Mol.F. | C13H22N4OS |
| Mol.Wt. | 282.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141228 |
| CAS No | NA |
| Mol.F. | C13H21N5O2S |
| Mol.Wt. | 311.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141229 |
| CAS No | NA |
| Mol.F. | C20H30N8O2S2 |
| Mol.Wt. | 478.6 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141230 |
| CAS No | NA |
| Mol.F. | C20H31N7OS2 |
| Mol.Wt. | 449.6 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141231 |
| CAS No | NA |
| Mol.F. | C10H16N4OS |
| Mol.Wt. | 240.3 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141232 |
| CAS No | NA |
| Mol.F. | C17H13N5O3 |
| Mol.Wt. | 335.3 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141233 |
| CAS No | NA |
| Mol.F. | C9H9N3O2 |
| Mol.Wt. | 191.2 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141234 |
| CAS No | NA |
| Mol.F. | C28H21F3N8O3 |
| Mol.Wt. | 574.5 |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0141235 |
| CAS No | NA |
| Mol.F. | C26H23N5O5 |
| Mol.Wt. | 485.5 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141236 |
| CAS No | NA |
| Mol.F. | C27H19F3N8O2 : HCl |
| Mol.Wt. | 544.5 : 36.5 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141237 |
| CAS No | NA |
| Mol.F. | C19H17N5O3 |
| Mol.Wt. | 363.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141238 |
| CAS No | NA |
| Mol.F. | C27H25N5O5 |
| Mol.Wt. | 499.5 |
| INV STATUS | CUSTOM SYNTHESIS |